CD8A and breast cancer: RBMS1 ablation significantly reduced PD-L1 level, thus to stimulate CD8+ CTL population and Granzyme B release and enhance the T-cell-mediated cancer cell killing, suggesting that RBMS1 plays an important role in breast cancer immunotherapy regulation.